Psychiatric Drugs Explained
- 6th Edition - January 21, 2016
- Author: David Healy
- Language: English
- eBook ISBN:9 7 8 - 0 - 7 0 2 0 - 4 6 8 8 - 9
Now in its sixth edition, and written by an author internationally recognised in his field, Psychiatric Drugs Explained offers a wealth of information in a handy easy-to-use fo… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNow in its sixth edition, and written by an author internationally recognised in his field, Psychiatric Drugs Explained offers a wealth of information in a handy easy-to-use format. Organised by disorder, and providing a comprehensive review of drug effects, action and side-effects, this fully updated new edition covers the latest drugs on the market, and explores changes in prescribing practice.
The author’s approach is distinctive and reader-friendly, to help guide mental health professionals through the benefits and impacts of psychotropic drugs. Additional topics include management of disorders including stimulants and drugs for children, cognitive impairment and sleep disorders.
- Includes management of disorders including stimulants and drugs for children, cognitive impairment and sleep disorders
- Gives particular focus on areas that are of major concern to mental health practitioners including management of dependence and withdrawal and issues of consent, abuse and liability
- ‘User Issues’ boxes highlight the most crucial aspects of drug effects and their implications
- Key references point the reader to the most up-to-date research and literature in the field
Psychiatric Drugs Explained will be ideal for mental health nurses, MRCPsych students, as well as social workers in mental health, clinical psychologists, pharmacologists and pharmacology students, community mental health professionals and GPs, advocacy and user groups in mental health, users and their families.
- Cover image
- Title page
- Table of Contents
- Copyright
- Preface
- Introduction
- List of Illustrations
- List of Tables
- Chapter 1: The person on treatment
- Chapter Contents
- Christmas Tree Light Bulb Test
- Section 1: Management of the Psychoses
- Chapter 2: The antipsychotics
- Chapter Contents
- Introduction
- History of the Antipsychotics
- Are Antipsychotics Antischizophrenic?
- How Antipsychotics Work
- A ‘Who Cares’ Feeling
- Antipsychotics and Positive Symptoms of Psychosis
- Antipsychotics and Negative Schizophrenia
- Clozapine and Second-Generation Antipsychotics
- Antipsychotic Doses
- Flexible Therapy
- For How Long Should Treatment Continue?
- Depot Antipsychotics
- Antiemetics
- Antipsychotics and Psychotherapy
- Significant Interactions
- Special Conditions
- Chapter 3: Antipsychotic side effects and their management
- Chapter Contents
- Introduction
- Dopamine System Effects and Side Effects
- Non-Dopamine Side Effects
- Management of Side Effects
- Section 2: Management of Depression
- Chapter 4: The antidepressants
- Chapter Contents
- Introduction
- History
- Depression
- Do Antidepressants Work?
- What Do Antidepressants Do?
- Antidepressants: First Choice or Last Resort?
- Starting Antidepressants
- Stopping Antidepressants
- Chapter 5: Side effects of antidepressants
- Chapter Contents
- Introduction
- The Ambiguous Side Effects of Antidepressants
- Effects Special to the MAOIs
- Interactions
- Section 3: Management of Bipolar Disorders
- Chapter 6: Management of acute bipolar disorder
- Chapter Contents
- Introduction
- Lithium for Mania
- Antipsychotics for Mania
- Anticonvulsants for Mania
- Carbamazepine
- Sodium Valproate
- Lamotrigine, Gabapentin and Oxcarbazepine
- Topiramate and Vigabatrin
- Acetazolamide
- Electroconvulsive Therapy (ECT)
- Benzodiazepines
- Do Antidepressants Cause Mania?
- Bipolar-Mania
- Chapter 7: Mood-stabilisers
- Chapter Contents
- History of Mood-Stabilisation
- Lithium as a Mood-Stabiliser
- The Anticonvulsant Mood-Stabilisers
- Carbamazepine and Oxcarbazepine
- Sodium and Semi-Sodium Valproate
- Lamotrigine
- Gabapentin and Pregabalin
- Topiramate and Levetiracetam
- Antipsychotics as Mood-Stabilisers
- Cocktail Treatment
- Coda
- Section 4: Stimulants and Drugs for Children
- Chapter 8: Stimulants and drugs for children
- Chapter Contents
- The History of the Stimulants
- The Emergence of ADHD
- Stimulant Treatment for ADHD
- Non-Stimulant Drug Treatments of ADHD
- Non-Drug Treatments of ADHD
- Other Uses of Stimulants
- Psychotropic Drugs and Children: General Principles
- The Use of Antidepressants for Children
- The Use of Antipsychotics for Children
- Section 5: Management of Anxiety
- Chapter 9: The anxiety disorders
- Chapter Contents
- Drugs Used in Anxiety
- Types of Anxiety
- Forms of Anxiety
- The Notion of an Anxiolytic
- Chapter 10: Benzodiazepine anxiolytics
- Chapter Contents
- Introduction
- Mechanism of Action of the Benzodiazepines
- Classes of Benzodiazepines
- Clinical Uses for Benzodiazepines
- Benzodiazepine Dependence and Withdrawal
- Chapter 11: Anxiolysis and the serotonin system
- Chapter Contents
- Introduction
- Serotonergic Receptors and Drugs
- Serotonin and Anxiolysis
- Chapter 12: Beta-blockers and anxiety
- Chapter Contents
- Introduction
- Performance-Related Anxiety
- Generalised Anxiety Disorder (GAD)
- Panic Attacks: A Puzzle?
- Tremor
- Akathisia and Restlessness
- Prazosin and Post-Traumatic Stress Disorder (PTSD)
- Section 6: Management of Sleep Disorders and Insomnia
- Chapter 13: Sleep disorders and insomnia
- Chapter Contents
- Introduction
- The Sleep Disorders
- Insomnia
- Chapter 14: Non-pharmacological management of insomnia
- Chapter Contents
- Caffeine
- Environmental Factors
- Relaxation
- Body Awareness
- Stimulus-Control Treatments
- Routines
- Paradoxical Intention
- Forward Planning
- Use of Mantras and Yogic Breathing Exercises
- Chapter 15: Hypnotics
- Chapter Contents
- Introduction
- Common Hypnotics
- Chapter 16: Sedatives
- Chapter Contents
- Melatonin and its Analogues
- Chloral Compounds
- Barbiturates and Related Compounds
- Chlormethiazole
- Sedative Antidepressants and Antipsychotics
- Antihistamines
- Section 7: Management of Cognitive Impairment
- Chapter 17: Cognitive enhancement and the dementias
- Chapter Contents
- Introduction
- The Dementias
- Chapter 18: Cognitive enhancement and neuroprotection
- Chapter Contents
- Introduction
- Second-Generation Cholinomimetics
- Cholinomimetics in Other Therapeutic Areas
- Memantine (Evista)
- Management of Multi-Infarct Dementia
- Management of Subcortical Dementias
- Neuroprotection
- Cognitive Enhancement and the Politics of Diagnosis
- Smart Drugs
- Section 8: Management of Sexual Difficulties
- Chapter 19: The range of sexual difficulties
- Chapter Contents
- Introduction
- Male Potency
- Ejaculation and Orgasm in Men
- Libido
- Sexual Orientation, Objects and Practices
- Sexual Responses in Women
- Chapter 20: Effects of drugs on aspects of sexual functioning
- Chapter Contents
- Drug Effects on Sexual Function: Males (see Appendix 20.1)
- Drug Effects on Sexual Function: Females (see Appendix 20.2)
- Aphrodisiacs
- Yohimbine, Trazodone and Cyproheptadine
- Intrapenile Treatments
- Phosphodiesterase Inhibitors
- Anti-Aphrodisiacs
- Persistent SSRI-Induced Sexual Dysfunction (PSSD)
- Appendix 20.1
- Appendix 20.2
- Section 9: Management of Dependence and Withdrawal
- Chapter 21: Dependence and withdrawal
- Chapter Contents
- Introduction
- Rebound Symptoms
- Withdrawal Syndromes
- Brain Physiology
- Tolerance
- Withdrawal Syndrome
- Chapter 22: Dependence and craving
- Chapter Contents
- Introduction
- Craving
- Behavioural Sensitisation
- Appetites
- Pharmacological Management of Appetites
- Psychological Factors in Substance Abuse
- Disinhibition
- Chapter 23: Dependence and protracted withdrawal
- Chapter Contents
- Historical Perspective
- Antipsychotic and Antidepressant Dependence
- Stress Syndromes
- Protracted Withdrawal or Legacy Effects?
- Section 10: Consent, Abuse and Liability
- Chapter 24: Consent
- Chapter Contents
- Introduction
- Voluntary Consent
- Information and Comprehension
- Clinical Trials and Legal Jeopardy
- Compliance
- Prescribing
- Chapter 25: Pharmacological abuse
- Chapter Contents
- The Problem
- The Dynamics of Abuse
- Prescription ‘Rights’
- The Right Not to be Disabled by Treatment
- Section 11: The Marketing of Tranquillity
- Chapter 26: The ethical industry
- Chapter Contents
- Introduction
- The Magic Bullet
- The Interface between Ethics and Markets
- Consequences
- Chapter 27: Evidence-biased care
- Chapter Contents
- Access to Data
- The Origin of Randomised Trials
- The Placebo Effect
- RCTs and Efficacy
- What's Wrong with RCTs?
- RCTs are Risky
- Chapter 28: Marketing and risk
- Chapter Contents
- The Marketing of Depression
- The Marketing of Bipolar Disorder
- The Marketing of Female Sexual Dysfunction
- Rating Scale Mongering
- Risk Management
- The New Marketing
- Chapter 29: From healthcare to pharmageddon
- Chapter Contents
- Perceptions of Progress in Mental Health
- Healthcare versus Health Products Ltd
- Pharmageddon
- Index
- Language: English
- Edition: 6
- Published: January 21, 2016
- Imprint: Churchill Livingstone
- eBook ISBN: 9780702046889
DH